2017年4月8日, 國際頂尖學術期刊《Science》旗下《 Science Translational Medicine》雜誌上線上發表了第二軍醫大學基礎醫學部雷長海教授和胡適博士課題組的一篇研究論文, 研究報導了一種新型腫瘤靶向治療策略, 並自主製備了一種新型抗體藥物, 有效阻止腫瘤生長。
在腫瘤的分子靶向治療中, 一種被稱為EGFR的分子靶向藥物常結合放射治療使用。 然而, 該療法僅在初期見效, 長用則易產生抗藥性。 為克服這一難題, 課題組致力於腫瘤細胞中具有幹細胞特徵的“腫瘤幹細胞”(CSC)研究。 腫瘤幹細胞對癌症復發和轉移影響很大, 只有同時抑制腫瘤實體細胞和腫瘤幹細胞,
原文連結:
原文摘要:
Epidermal growth factor receptor (EGFR) blockade and radiation are efficacious in the treatment of cancer, but resistance is commonly reported. Studies have suggested that dysregulation of Notch signaling and enrichment of the cancer stem cell population underlie these treatment challenges. Our data show that dual targeting of EGFR and Notch2/3 receptors with antibody CT16 not only inhibited signaling mediated by these receptors but also showed a strong anti–stem cell effect both in vitro and in vivo. Treatment with CT16 prevented acquired resistance to EGFR inhibitors and radiation in non–small cell lung cancer (NSCLC) cell line models and patient-derived xenograft tumors. CT16 also had a superior radiosensitizing impact compared with EGFR inhibitors. CT16 in combination with radiation had a larger antitumor effect than the combination of radiation with EGFR inhibitors or tarextumab. Mechanistically, CT16 treatment inhibits the stem cell–like subpopulation, which has a high mesenchymal gene expression and DNA repair activity, and reduces tumor-initiating cell frequency. This finding highlights the capacity of a combined blockade of EGFR and Notch signaling to augment the response to radiation and suggests that CT16 may achieve clinical efficacy when combined with radiation in NSCLC treatment.